Abstract
dc:description.abstractRecent research has highlighted the connection between dysbiosis of the gut microbiome and its role in the development of Irritable Bowel Syndrome (IBS). Over the last few years, probiotics have grown in popularity as a potential treatment option in IBS. However, most current probiotic studies are limited due to small study populations, older median age, and short study time duration. The proposed study will be a multicenter, randomized, double-blinded placebo controlled study comparing the multi-strain probiotic Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium breve, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Escherichia coli DSM17252 to placebo in patients diagnosed with IBS based on Rome IV criteria over a 3-months duration. The study participants will have a baseline evaluation and a final evaluation at the end of the 3-months duration. The primary outcome will be the IBS Symptom Severity Score and the secondary outcomes will the individual components of the IBS Symptom Severity Score. The results of this study will begin to fill gaps in the current knowledge of the use of probiotics in the treatment of IBS.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Physician Assistant Program
- Grantor
- Boston University
- Year dc:date.issued
- 2021
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Martinez, Sarah Ann
- Advisors dc:contributor.advisor
-
- Weber, Horst C.
- Weinstein , John R.
Subjects
dc:subject × 4Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/43865